Press Release
Arrakis Therapeutics Announces Presentations at Upcoming Scientific Meetings
Waltham, Mass., April 2, 2024 – Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced that the company will participate in five upcoming scientific conferences. Arrakis scientific leaders will present data on the company’s advances in the discovery of RNA-targeted small molecules.
Details of the Arrakis presentations are as follows:
American Chemical Society Spring 2024 Annual Meeting, New Orleans
Presentation: Division of Medicinal Chemistry, general oral presentation on RNA-targeted small molecules
Date: Wednesday, March 20
Presenter: Jennifer Petter, PhD, Founder & Chief Scientific Officer
Drug Discovery Chemistry, San Diego, CA
Presentation Title: Recent Advances in the Discovery of RNA-Targeted Small Molecules
Date: Thursday, April 4
Time: 10:45 a.m. PT
Presenter: Karthik Iyer, PhD, Director, Medicinal Chemistry
American Association for Cancer Research, San Diego, CA
Presentation Title: Discovery of RNA-targeted Small Molecule Therapeutics
Session: Chemistry to the Clinic Part 2 of 3: Considerations in the Discovery of Small Molecules Targeting RNA
Date: Saturday, April 6
Time: 12:30 p.m. PT
Presenter: Kathleen McGinness, PhD, Vice President, Platform Biology
Biophysics for Drug Discovery Summit, Boston, MA
Presentation Title: Approaches for Characterizing the Structure of Novel Targets
Date: Tuesday, April 23
Time: 1:30 p.m. ET
Presenter: Aaron Frank, PhD, Director, Computational Chemistry
National Cancer Institute’s 2024 RNA Biology Initiative Workshop: RNA Therapeutics
Presentation: A Structure Based Approach to Drugging RNA
Date: Tuesday, April 23
Presenter: Jennifer Petter, PhD, Founder & Chief Scientific Officer
About Arrakis Therapeutics
Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. Arrakis is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and genetically validated targets in other disease areas. The company brings together scientific leaders in RNA structure, chemistry and biology, along with a highly experienced management team and the backing of leading life sciences investors. The company is located in Waltham, Massachusetts. For more information, please visit www.arrakistx.com and engage with us on Twitter @ArrakisTx or on LinkedIn.
